The pattern and time course of ADAMTS13 activity recovery in our study was generally consistent with previous reports in European individuals with acquired TTP [18, 20, 21], although recovery of ADAMTS13 activity in our study was faster than in a real-world German study of caplacizumab treatment, in which the median time to ADAMTS13 activity > 10% was 21 days after starting TPE (a week longer than in our study) [21]. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.